Abstract
The risks of malignancy for cytologic categories in renal biopsy specimens differ from the risks in most other sites. There are obvious areas in which cytopathologists can do better at classifying these cases, and the routine use of immunohistochemistry and core-needle biopsy may improve the accuracy of the classification of these specimens.
Publication Date
3-1-2024
Content Type
Article
PubMed ID:
Citation
Renshaw, A. A., & Pitman, M. B. (2024). Risk of malignancy in renal biopsy: A review. Cancer cytopathology, 132(3), 140–143. https://doi.org/10.1002/cncy.22759
Comments
Copyright: © 2024. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY. 4.0)